DIAGNOS Inc.
TSX VENTURE : ADK

DIAGNOS Inc.

July 05, 2016 10:53 ET

DIAGNOS Announces Operational Update of a Contract in India Valued at Up to $1.3M

BROSSARD, QUEBEC--(Marketwired - July 5, 2016) - Diagnos Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announces today that it has successfully expanded its healthcare operations to three additional cities in India through its subsidiary, Diagnos Healthcare India Pvt. Ltd.

The expansion agreement, announced on September 23rd, 2015, valued at up to $1.3M as per our estimated level of transactions, is being executed with a global pharmaceutical partner. Our operations in India now include a total of four mobile screening units, one in each of the following cities: Mumbai, Delhi, Chennai and Kolkata. For each of the cities, DIAGNOS provides a complete screening solution comprised of project managers, technicians, image interpretation services, branded vans and drivers, the CARA telemedicine platform, fundus cameras and accessories.

"Since our first announcement of the project in 2013 we have screened thousands of patients in Mumbai and the surrounding area. Our client, along with patients and the clinics used as screening locations, have responded extremely positively to our screening services and we have seen 300% growth in patient volume since February of this year and an average of 1,400 patients per month. As a result of the success of the first screening unit, the new screening units function exactly the same way as the original one in Mumbai. We are excited to have expanded to other cities in India and look forward to continuing to grow in the country," said André Larente, DIAGNOS' President.

About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.

About CARA

CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA's image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real-time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, and the European Union.

Forward-looking information

This document contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these
statements.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact DIAGNOS, visit our website at www.diagnos.com, or visit the SEDAR website at www.sedar.com.

Contact Information

  • Andre Larente
    President
    (450) 678-8882, ext. 224